Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.

Hamm CA, Pry K, Lu J, Bacus S.

Exp Mol Pathol. 2019 Aug;109:1-15. doi: 10.1016/j.yexmp.2019.04.004. Epub 2019 Apr 3.

PMID:
30953647
2.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K.

Clin Cancer Res. 2017 Jun 15;23(12):2991-3002. doi: 10.1158/1078-0432.CCR-16-2217. Epub 2016 Nov 23.

3.

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.

Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, Cristofanilli M, Bacus S.

Mol Cancer Ther. 2016 Jul;15(7):1746-56. doi: 10.1158/1535-7163.MCT-15-0353. Epub 2016 Apr 19.

4.

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.

Spector NL, Robertson FC, Bacus S, Blackwell K, Smith DA, Glenn K, Cartee L, Harris J, Kimbrough CL, Gittelman M, Avisar E, Beitsch P, Koch KM.

PLoS One. 2015 Nov 16;10(11):e0142845. doi: 10.1371/journal.pone.0142845. eCollection 2015.

5.

Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.

Doherty KR, Talbert DR, Trusk PB, Moran DM, Shell SA, Bacus S.

Toxicol Appl Pharmacol. 2015 May 15;285(1):51-60. doi: 10.1016/j.taap.2015.03.008. Epub 2015 Apr 2.

PMID:
25841593
6.

A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.

Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S.

Toxicol Sci. 2015 Jan;143(1):147-55. doi: 10.1093/toxsci/kfu215. Epub 2014 Oct 10.

PMID:
25304212
7.

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.

Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS.

Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.

8.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

9.

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.

Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S.

Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55. doi: 10.1016/j.taap.2013.04.027. Epub 2013 May 21.

PMID:
23707608
10.

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.

Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Köstler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y.

Oncogene. 2012 Jul 26;31(30):3505-15. doi: 10.1038/onc.2011.518. Epub 2011 Nov 21.

11.

Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.

Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL.

Clin Cancer Res. 2011 Sep 15;17(18):6061-70. doi: 10.1158/1078-0432.CCR-11-1071. Epub 2011 Aug 2.

12.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

13.

Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.

Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, Feingold JM, Zacharchuk C, Berkenblit A.

Breast Cancer Res Treat. 2010 Nov;124(1):1-11. doi: 10.1007/s10549-010-1108-4. Epub 2010 Aug 28. Review.

PMID:
20803067
14.

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ.

Clin Cancer Res. 2010 Mar 15;16(6):1904-14. doi: 10.1158/1078-0432.CCR-09-2282. Epub 2010 Mar 9.

15.

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA 3rd, Thompson JW, Chen FL, Koch KM, Spector NL.

Mol Cancer Ther. 2010 Feb;9(2):292-9. doi: 10.1158/1535-7163.MCT-09-1041. Epub 2010 Feb 2.

16.

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.

Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS.

Cell Cycle. 2008 Jun 15;7(12):1769-75. Epub 2008 Jun 30.

PMID:
18594201
17.

A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.

Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y.

Nat Cell Biol. 2007 Aug;9(8):961-9. Epub 2007 Jul 22.

PMID:
17643115
18.

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.

Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10607-12. Epub 2007 Jun 7.

19.

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL.

Cancer Res. 2007 Feb 1;67(3):1170-5.

20.

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. Epub 2006 May 8.

21.

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.

Cancer Res. 2006 Feb 1;66(3):1640-7.

22.

The era of ErbB-receptor-targeted therapies: advances toward personalized medicine.

Bacus S, Spector NL, Yarden Y.

Per Med. 2005 Nov;2(4):301-315. doi: 10.2217/17410541.2.4.301.

PMID:
29788579
23.
24.

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.

J Clin Oncol. 2005 Apr 10;23(11):2502-12. Epub 2005 Jan 31.

PMID:
15684311
25.

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1915-20. Epub 2005 Jan 31.

26.

Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.

Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, Yarden Y.

J Biol Chem. 2005 Mar 4;280(9):8503-12. Epub 2004 Dec 17.

27.
28.

Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.

Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS.

Cancer. 2004 Feb 1;100(3):499-506.

29.

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M.

Clin Cancer Res. 2003 Jul;9(7):2478-86.

30.

Cyclin E and survival in patients with breast cancer.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS.

N Engl J Med. 2002 Nov 14;347(20):1566-75. Erratum in: N Engl J Med 2003 Jan 9;348(2):186.

31.

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.

Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR.

Oncogene. 2002 May 16;21(22):3532-40.

32.

Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS.

Pathol Oncol Res. 2001;7(3):171-7.

33.

Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes.

Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group.

Am J Ophthalmol. 2001 Jun;131(6):788-91.

PMID:
11384577
34.

Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.

Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R.

Oncogene. 2001 Jan 11;20(2):147-55.

35.

ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y.

Mol Cell Biol. 1998 Oct;18(10):6090-101. Erratum in: Mol Cell Biol 1998 Dec;18(12):7602. Alamandi M [corrected to Alimandi M].

36.

Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.

Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y.

J Biol Chem. 1998 Apr 24;273(17):10496-505.

37.

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.

Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.

Oncogene. 1998 Mar 12;16(10):1249-58.

38.
39.

Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma.

Cohen BD, Siegall CB, Bacus S, Foy L, Green JM, Hellström I, Hellström KE, Fell HP.

Biochem Soc Symp. 1998;63:199-210. Review.

PMID:
9513724
40.

Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus.

Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, Gudkov AV.

Cancer Res. 1997 Dec 1;57(23):5217-20.

41.

Evaluation of newer prognostic markers for adult soft tissue sarcomas.

Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson IB, Das Gupta TK.

J Clin Oncol. 1997 Oct;15(10):3249-57.

PMID:
9336362
42.

Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers.

Bacus S, Chin D, Stewart J, Zelnick C, Mahvi D, Gilchrist K.

Anal Quant Cytol Histol. 1997 Aug;19(4):316-28. Review.

PMID:
9267565
43.

Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV.

EMBO J. 1997 Mar 17;16(6):1391-400.

44.

Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.

Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K.

Oncogene. 1996 Jun 20;12(12):2535-47.

PMID:
8700512
45.

An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.

Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y.

J Biol Chem. 1996 Mar 29;271(13):7620-9.

46.
47.
48.

HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.

Siegall CB, Bacus SS, Cohen BD, Plowman GD, Mixan B, Chace D, Chin DM, Goetze A, Green JM, Hellström I, et al.

J Biol Chem. 1995 Mar 31;270(13):7625-30.

49.

Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior.

Bacus SS, Zelnick CR, Chin DM, Yarden Y, Kaminsky DB, Bennington J, Wen D, Marcus JN, Page DL.

Am J Pathol. 1994 Dec;145(6):1337-48.

50.

Supplemental Content

Support Center